Compare FLNG & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNG | AGIO |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2019 | 2013 |
| Metric | FLNG | AGIO |
|---|---|---|
| Price | $29.50 | $29.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $23.00 | ★ $38.88 |
| AVG Volume (30 Days) | 448.5K | ★ 750.9K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | ★ 9.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $76.75 |
| Revenue Next Year | $2.14 | $170.73 |
| P/E Ratio | $19.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.72 | $22.24 |
| 52 Week High | $33.40 | $46.00 |
| Indicator | FLNG | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.77 | 54.44 |
| Support Level | $28.62 | $26.75 |
| Resistance Level | $30.84 | $30.90 |
| Average True Range (ATR) | 0.82 | 1.09 |
| MACD | -0.35 | 0.28 |
| Stochastic Oscillator | 9.02 | 64.94 |
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The company's fleet consists of several LNG carriers on the water, and all of its vessels are of the latest generation equipped with two-stroke propulsion. Its fleet consists of M-type, Electronically Controlled, Gas Injection (MEGI) LNG carriers and Generation X Dual Fuel (X-DF) LNG carriers, offering improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. The company has one reportable segment: vessel operations, which generates revenue from the chartering of vessels to customers.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.